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Key points 
EPHB2 tyrosine kinase receptor plays an important role in platelet function through cross-talk 
with GPVI and GPRC signaling. 
 
A novel EPHB2 variant causes an inherited platelet function disorder. 
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Abstract 
 
The ephrin transmembrane receptor (EPHR) family of tyrosine kinases is involved in 
platelet function. We report the first EPHB2 variant affecting platelets in two siblings (P1 
and P2) from a consanguineous family with recurrent bleeding and normal platelet 
counts. Whole exome sequencing identified a c.2233C>T variant (missense p.R745C) of 
the EPHB2 gene. P1 and P2 were homozygous for this variant while their asymptomatic 
parents were heterozygous. The p.R745C variant within the tyrosine kinase domain was 
associated with defects in platelet aggregation, αIIbβ3 activation and granule secretion 
induced by GPCR (G protein-coupled receptors) agonists and convulxin as well as in 
thrombus formation on collagen under flow. In contrast, clot retraction, flow-dependent 
platelet adhesion and spreading on fibrinogen were only mildly affected indicating limited 
effects on αIIbβ3 outside-in signaling. Most importantly, Lyn, Syk and FcRγ 
phosphorylation, the initial steps in GPVI platelet signaling were drastically impaired in 
the absence of platelet-platelet contact indicating a positive role for EPHB2 in GPVI 
activation. Likewise platelet activation by PAR4-AP showed defective Src activation, as 
opposed to normal PKCs activity and Ca2+ mobilization. Overexpression of wild-type 
(WT) and R745C EPHB2 variant in RBL-2H3 cells (Rat Basophilic Leukemia cells) stably 
expressing human GPVI, confirmed EPHB2 R745C mutation impaired EPHB2 
autophosphorylation, but had no effect on ephrin ligand-induced EPHB2 clustering, 
suggesting it did not interfere with EPHB2-ephrin-mediated cell-to-cell contact. In 
conclusion, this novel inherited platelet disorder affecting EPHB2 demonstrates this 
tyrosine kinase receptor plays an important role in platelet functions, through a cross-talk 
with GPVI and GPCR signaling.   
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Introduction 
EPH receptors (erythropoietin-producing hepatoma-amplified sequence) are a large 
family of transmembrane tyrosine kinases that interact with ephrin ligands. These 
receptors, composed of an N-terminal glycosylated ligand-binding domain, a 
transmembrane region and an intracellular kinase domain, are divided into two 
subclasses A and B, based on sequence similarity and ligand affinity. Their ligands are 
also divided into two subclasses, the A-subclass [A1-A6] which is tethered to the cell 
membrane by a glycosylphosphatidylinositol anchor and the B-subclass [B1-B3] which 
has a transmembrane domain followed by a short cytoplasmic region. Generally, 
ephrinA ligands bind to EPHA receptors, while the ephrinB ligands bind to the EPHB 
receptors. One exception is EPHA4 that can bind both ephrinsA and B. Ligand-receptor 
interactions initiate clustering, tyrosine phosphorylation and signaling of EPHs.1,2 Cell 
surface clustering of the ligated ephrins elicits signaling in ephrin-bearing cells.3,4 EPH 
receptors and ephrins are expressed in virtually all tissues and they are involved in 
several biological functions including vascular development, tissue border formation, cell 
migration, axon guidance2, memory learning,5 bone homeostasis,6 insulin secretion7 and 
neurological development. These cellular responses to EPH-ephrin signaling also 
include changes in the actin cytoskeleton, cell-substrate adhesion, cell motility as well as 
modulation of cell survival and proliferation. Finally EPH-ephrins are involved in various 
pathologies such as neurological disorders and cancer in which EPHs and ephrins 
function during tumor invasion, neoangiogenesis and metastasis.1,8 Indeed, several 
EPHs have been shown to exhibit tumor suppressor roles in prostate, colon and breast 
tumors9-11 prompting their exploration as potential therapeutic targets.  
Human platelets are known to express EPHA4, EPHB1 and its ligand ephrinB1.12-14 They 
promote platelet adhesion and aggregation as well as stability of the hemostatic plug, 
whereas inhibition of the EPH/ephrin interaction leads to disaggregation at low doses of 
agonists. EPHA4 and EPHB1 are also involved in adhesion to the fibrinogen matrix, 
triggering tyrosine phosphorylation of the β3 cytoplasmic domain of αIIbβ3 and αIIbβ3-
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mediated outside-in signaling controlling platelet spreading and platelet retraction. 
Recently, Vaiyapuri et al15 using transgenic mice (EPHB2LacZ) expressing a chimeric 
EPHB2-β-galactosidase protein (with preserved ephrin binding but abrogated tyrosine 
kinase activity) concluded that EPHB2 was involved in the regulation of thrombus 
formation and retraction. Most importantly, they showed that the cytoplasmic tail of 
EPHB2 regulates platelet activation in a contact-independent manner in the absence of 
EPHB2-ephrin ligation between platelets. 
We now report a new recessive bleeding disorder with impaired platelet function and a 
signaling defect that cosegregates with a predicted disease-causing EPHB2 gene 
variant affecting the EPHB2 receptor. The missense homozygous mutation p.R745C is 
located in the tyrosine kinase domain of EPHB2 and modifies a potential 
phosphorylation site. Both affected siblings from a consanguineous family were 
homozygous for the mutation. The defect gives impaired platelet aggregation and 
secretion induced by various agonists (thrombin, ADP and convulxin (Cvx), decreased 
adhesion and thrombus formation on collagen with modified GPVI and GPCR signaling. 
Overexpression of wild-type and variant EPHB2 in Rat Basophilic Leukemia (RBL)-2H3 
cells stably expressing human GPVI suggests that EPHB2 regulates positively GPVI 
signaling.  
 
Methods 
Further details of material and methods are provided in supplemental data. 
Patients.  
Two patients, brother (P1) and sister (P2) with an inherited bleeding syndrome were the 
object of clinical and biological studies in the Bordeaux Reference Center for Platelet 
Pathologies prior to being enrolled within the BRIDGE-Bleeding and Platelet Diseases 
(BPD) cohort (UK REC10/H0304/66) (Cambridge, UK) after informed consent and in 
accordance with the Declaration of Helsinki. Studies were performed under the 
promotion of the Ethics Committee of Ile de France IV (IRB 00003835). Whole exome 
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sequencing (WES) identified a list of about 200 variants for each patient that were then 
assessed taking into account the consanguinity of the family and their phenotype.  
 
EPHB2 expression in cell line 
EPHB2-R745C cDNA was generated by site directed mutagenesis of the full-length wild-
type (WT) EPHB2 cDNA fused to the fluorescent reporter protein GFP and inserted in 
the pcDNA3 expression vector. WT or mutant EPHB2 cDNAs were transiently 
transfected into RBL-2H3 cells16 by nucleofection using the Neon transfection system 
(Invitrogen-ThermoFisher Scientific, Saint-Aubin, France) according to the 
manufacturer’s instructions (1 µg of plasmid DNA for 105 cells). 
 
Statistical Analysis 
The presented results are mean ± Standard Error of the Mean (SEM).  Data distribution 
was analyzed using the Student t test or 1-way ANOVA followed by Tukey’s multiple 
comparison test. P-values<0.05 were considered as statistically significant (* P<0.05, ** 
P<0.01, *** P<0.001). Results with P-value>0.05 were considered as not significant. 
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Results 
 
Patient characterization 
The two affected patients are siblings of a consanguineous family (pedigree in Figure 
1A). The brother P1 and his sister P2, now young adults, were respectively 12 and 15 
years old when initial platelet investigations were performed (Table S1). In both cases 
excessive spontaneous subcutaneous bleeding, and heavy bleeding after minor wounds 
were observed. In addition P1 developed during childhood an anemia resulting from 
chronic gastro-intestinal bleeding requiring iron treatment. The ISTH-BAT-bleeding 
score17 was 11 for P1 and 6 for P2. No other associated syndromes were observed. 
Both parents were asymptomatic. The platelet count was normal for all family members, 
but in a recent investigation (10 years later) a mild decrease in platelet count was noted 
for P1 (120x109 platelets/L). Other hematopoietic lineages were normal for all the family 
(Table S1). The initial platelet function investigations revealed a decreased response to 
ADP, arachidonic acid, collagen and U46619 but a normal response to ristocetin (Table 
S1). Platelet responses were normal for both parents. Evaluation of platelet ATP/ADP 
content using the luciferin-luciferase procedure and dense granule number evaluated by 
whole mount electron microscopy revealed normal values for the patients P1 and P2 and 
their parents (Table S2). Other platelet function investigations detailed below were 
performed after the EPHB2 variant was selected as the primary disease-causing 
candidate. 
 
Genetic analysis 
Six non-synonymous homozygous rare variants shared by the two patients were 
identified by whole exome sequencing (WES) (Table S3) provided by BRIDGE-BPD, 
including p.R745C EPHB2. On the basis of the clinical and biological phenotype of both 
patients and similarities with the recent phenotype published for the β-Gal-EPHB2 
transgenic mouse model15, EPHB2 was selected as the most likely candidate gene. This 
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gene located on chromosome 1 encodes the EPHB2 receptor tyrosine kinase. The 
homozygous c.2233C>T transition was predicted to give rise to a p.R745C missense 
variant of the EPHB2 protein (transcript NM_004442.6). PolyPhen-2 software and the 
Sift score predicted the variant to be damaging with high probability. This EPHB2 variant 
was present in the ExAC database at minor allele frequency (MAF)<10-6 showing that it 
is not a common polymorphism. Sanger sequencing of this variant in all individuals of 
the family confirmed that P1 and P2 were homozygous for the c.2233C>T transition 
whereas the parents were heterozygous (Figure 1B). Interestingly, the variant amino 
acid is located in the tyrosine kinase intracytoplasmic domain of the molecule affecting 
one of the predicted tyrosine kinase phosphorylation site (Figure 1C).18 Indeed, EPHB2 
phosphorylation on Y594/604 (EPHB2-p-Y594/604) located in the juxtamembrane 
domain and required for kinase activity was increased in control platelets induced by Cvx 
(800 pM) while phosphorylation of tyrosines 594/604 was diminished in P1 platelets 
(Figure 1D). The tyrosine kinase domain including R745 is highly conserved among the 
different animal species from homo sapiens to fish (D rerio), suggesting a strong 
functional impact for the R745C mutation. Finally, R745 is located immediately before 
D746, the presumed proton acceptor essential for ATP-dependent kinase active site of 
the EPHB2 kinase domain. It is thus likely that changing the bulky basic R745 for the 
much smaller neutral C745 will interfere with D746 function. 
None of the other five candidate rare variants were predicted to be disease causing and 
no other candidate mutations were present in any gene known to be associated with an 
inherited platelet-derived bleeding disorder.  
 
Morphological and structural characterization of patients’ platelets 
Platelet count and volume for both patients were normal during their adolescence 
whereas the platelet count slightly decreased for patient P1 when 21 years old. Electron 
microscopy revealed heterogeneity in platelet shape, while some platelets appeared thin, 
discoid and abnormally elongated, others were round (Figure 2a-f). A defect in 
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fragmentation was suggested by platelets with a sickle shape and extensions of the 
plasma membrane (Figure 2a,f). Some large fragments of MK were present in the blood 
(Figure 2c,g), as were barbel-shaped preplatelets (Figure 2e). Quantitative 
morphometric evaluation of platelets of both patients confirmed a mean increase in 
maximal diameter (P1: 3.61 ± 0.84 μm, p≤ 0.001, P2: 3.72 ± 0.83 μm, p≤0.001 versus 
control: 2.85 ± 0.15 μm) whereas the minimal diameter was close to normal values 
(Table S4). As a consequence the ratio between maximal and minimal diameter was 
much increased (P1: 2.79 ± 1.22, p≤0.1 and P2: 3.27 ± 1.49, p≤ 0.001 versus control: 
2.4 ± 0.1). The large standard deviation reflects the heterogeneity. For patient P1 with 
the recent slight decrease in platelet count the morphological platelet characteristics 
remain the same. Evaluation by manual counting of microtubule coils in electron 
microscopy photos revealed a similar number of microtubule coils for patient and control 
(control: 14.2 ± 4.6 microtubules versus P1: 14.6 ± 4.4 microtubules (not illustrated). 
Quantification of the levels of EPHB2 (Figure S1A) and other membrane receptors, 
GPVI, FcRγ, β1 and αIIbβ3 (Figure S1B), α-granule contents (fibrinogen), α-
granule/dense granule membrane marker (P-selectin) and β1-tubulin for microtubules 
(Figures S1C-E) were normal.  
 
EPHB2 variant associates with decreased platelet aggregation and αIIbβ3 
activation   
Because initial platelet characterization showed abnormal platelet function, we looked in 
detail at platelet aggregation, secretion and αIIbβ3 activation in both patients (P1 and 
P2). Aggregation of washed platelets induced by various concentrations of ADP (10 and 
20 μM), thrombin (25 and 50 mU/mL) and PAR4-AP (50 μM) was strongly impaired 
(Figures 3A-3C-4A) but secretion was only partially affected (dense and α-granules) in 
both patients (Figures 3E-3F-4C). Since aggregation requires αIIbβ3 activation, we next 
quantified αIIbβ3 activation by binding of PAC1, a mAb specific for the activated 
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conformation of human αIIbβ3 integrin. In the absence of stirring, αIIbβ3 activation 
induced by ADP, thrombin or PAR4-AP was totally abolished in both patients (Figures 
3B-3D-4B). We next investigated PAR4-AP-induced signaling after removal of secreted 
ADP by apyrase (2U/mL) and inhibition of thromboxane A2 synthesis by indomethacin 
(10 μM). Because no Ca2+ mobilization was observed with PAR4-AP (50 μM) in unstirred 
control platelets (results not shown), higher doses of PAR4-AP (100 μM and 200 μM) 
were used (Figure 4D). Ca2+ mobilization and phosphorylation of PKC substrates were 
similar in P1 and controls indicating that the activity of PLCβ3 was normal in P1 (Figure 
4D-4E). In contrast, no increase in PAR4-AP-induced Src activity, as assessed by the 
phosphorylation level of the amino acid Y418, was observed in P1 (Figure 4F) indicating 
that EPHB2 acts close to or directly on the tyrosine kinase Src and thus downstream of 
PLCβ3.  
Since EPHB2 has been shown to be important for GPVI signaling,15 we next investigated 
convulxin (Cvx)-induced platelet aggregation. Cvx (200 to 800 pM)-induced platelet 
aggregation was totally abolished in both patients at low doses of Cvx (P1: 200 pM, P2: 
200 and 400 pM) and drastically decreased at higher doses (Figure 5A). Similar results 
were obtained for collagen-induced platelet aggregation in platelet-rich-plasma (Table 
S1). In parallel PAC1 binding to αIIbβ3 in the patients’ platelets was completely 
abolished whatever the concentrations of Cvx used (200 to 800 pM) (Figure 5B). We 
next measured αIIbβ3 activation triggered by Cvx after removal of ADP by apyrase 
(2U/mL) and inhibition of thromboxane A2 synthesis by indomethacin (10 μM). The 
partial αIIbβ3 activation observed in control platelets under these conditions, was 
therefore directly dependent on GPVI (Figure 5C). The total absence of αIIbβ3 activation 
observed in patients’ platelets under the same conditions (apyrase and indomethacin) 
showed that the EPHB2 mutation directly affected GPVI signaling. Altogether, these 
results demonstrate that the EPHB2 mutation affects platelet aggregation and αIIbβ3 
activation in a manner both dependent and independent of GPVI signaling. 
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Convulxin-induced platelet secretion and thrombus formation on collagen matrix 
are impaired in patients with the EPHB2 variant. 
We next quantified dense and α-granule secretion by measuring ATP release and P-
selectin exposure. The total content of α-granule (fibrinogen) (Figure S1C) and dense 
granule secretion (ATP) was checked and confirmed to be normal (results not shown). In 
Cvx-induced aggregation, ATP release was decreased by 60 to 70% for P1 platelets and 
44 to 100% for P2 platelets compared with control platelets (Figure S2A). In unstirred 
conditions, P-selectin exposure at low dose of Cvx (200 pM) was 71% and 74% lower in 
P1 and P2 platelets than in control platelets (Figure S2B). The addition of apyrase 
(2U/mL) and indomethacin (10 μM) clearly showed that the decrease in P-selectin 
exposure is largely dependent on GPVI signaling in P1 and P2 (Figure S2C). Only a 
small part of P-selectin exposure was dependent on ADP release and TXA2 synthesis 
under unstirred conditions (Figures S2B-C).  
We next assessed the impact of this variant on adhesion and thrombus formation on a 
collagen matrix at arterial shear rate (1500 s-1). For these experiments, platelet counts 
were normalized. The area covered by P1 and P2 platelets was slightly lower reaching 
80.5% and 72.5% of controls (100%) (P1: P<0.01; P2: P<0.05) (Figure 5D, upper panel). 
Thrombus size was significantly decreased for P1 and P2 reaching 37.6% for P1 
(P<0.001) and 32.2% for P2 (P<0.001) (Figure 5D, bottom panel). On addition of 
apyrase and indomethacin the residual adhesive platelets and thrombus size were 
always significantly lower in P1 (P<0.05) and in P2 (P<0.001) compared with controls 
(Figure 5D); thus decreases for the patients’ platelets were both dependent and 
independent of GPVI signaling. Altogether, these results indicate that the EPHB2 
mutation affects secretion and GPVI signaling involved in thrombus formation. 
 
EPHB2 variant only mildly affects αIIbβ3 outside-in signaling  
For personal use only.on October 14, 2018. by guest  www.bloodjournal.orgFrom 
 12
Because EPHB2 has been reported to be physically associated with αIIbβ3 in mouse 
platelets, and to be involved in the regulation of the outside-in signaling,15 we next 
investigated the impact of this EPHB2 variant on αIIbβ3-mediated outside-in signaling. 
First, the kinetics of clot retraction was analyzed in platelet rich plasma (PRP) after 
addition of various concentrations of thrombin (0.1 and 0.5 U/mL). A reduction of clot 
retraction induced by 0.1U/mL thrombin was already observed at 20 minutes reaching 
53.8% and 38.2% of control values for P1 and P2; however after 1 hour of thrombin 
(0.1U/mL) or at a higher concentration of thrombin (0.5U/mL), clot retraction normalized 
(Figure S3A). Because the lower rate of clot retraction may be explained by a defective 
response to thrombin (thrombin-induced platelet aggregation and αIIbβ3 activation were 
partly decreased in P1 and P2: Figure 3C), we next examined adhesion to fibrinogen 
matrix (100 µg/mL) under low shear conditions (300 s-1) and in the presence of 
apyrase/indomethacin. Adhesion was moderately but significantly reduced, reaching 
79% (P<0.01) and 67% (P<0.01) of controls (100%) for P1 and P2 respectively (Figure 
S3B). Note that spreading on a fibrinogen matrix (100 µg/mL) under static conditions 
was also moderately decreased (78.5% of control) (Figure S3C). Altogether these 
results indicate that the EPHB2 variant only slightly alters platelet αIIbβ3 outside-in 
signaling. 
 
GPVI signaling pathway is impaired in the patients’ platelets.  
To get insight into the mechanism of the regulation of platelet function by EPHB2, we 
next examined the signaling pathway downstream of GPVI using unstirred platelets in 
the presence of apyrase/indomethacin, preventing superimposed signaling by ADP or 
thromboxane A2. First we assessed Ca2+ mobilization from intracellular stores, essential 
for platelet activation and secretion. Flow cytometry of Oregon Green BAPTA1-AM 
loaded platelets stimulated with Cvx (200 to 800 pM) showed a lower Ca2+ mobilization 
for P1 (Figure 6A) and P2 (Figure S4) whatever the concentration of agonist used. The 
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activation of PI3-kinase and PLCγ2, important players in GPVI signaling, as assessed by 
the phosphorylation level of its effector Akt (Akt: p-S473) and PLCγ2 (PLCγ2-p-1217) 
were totally or partially abolished for P1 (Figure 6B). We next examined the initial steps 
of GPVI signaling by measuring the phosphorylation of the tyrosine phosphorylation of 
the ITAM motif of FcRγ (FcRγ-P) and the tyrosine kinase Syk (Syk: p-Y525/526) 
associated with GPVI. Syk-P and FcRγ-P as detected by anti-Syk-P and anti-
phosphotyrosine antibodies, respectively, were also drastically impaired in P1 platelets 
(Figure 6C) strongly suggesting that EPHB2 regulates the first steps of the GPVI 
signaling pathway. Since the activation of Src kinases (Lyn, Fyn), constitutively 
associated with GPVI, plays a critical role in initiating GPVI signaling by mediating the 
phosphorylation of FcRγ and Syk on tyrosine residues, we next examined the 
phosphorylation of Lyn. Lyn contains 2 highly conserved tyrosine residues, the C-
terminal one exhibiting an inhibitory activity (Lyn: p-Y507), the other one being part of 
the activation loop (Lyn p-Tyr 396).19 Under our conditions, as expected, Lyn activation 
(Lyn p-Y396) was increased in control platelets after Cvx stimulation (Figure 6D). 
Conversely, no increased phosphorylation of Lyn p-Tyr 396 after Cvx stimulation was 
observed in P1 platelets. Altogether, these results confirm that EPHB2 acts during the 
initial step of GPVI signaling and independently of platelet-platelet contact. 
 
Confirmation of the effect of EPHB2 R745C mutation on EPHB2 function by 
overexpression in GPVI-expressing RBL-2H3 cells.   
One of the key features of EPH receptors is that they undergo autophosphorylation upon 
cross-linking, usually mediated by cell-cell contact and ephrin engagement. To test 
whether EPHB2 R745C mutation affected autophosphorylation in the absence of cell-cell 
contact, we made use of the RBL-2H3 cell line stably expressing recombinant human 
GPVI and in which WT- and EPHB2-variant constructs were overexpressed. The 
efficiency of transfection was between 30% to 40% for EPHB2-WT and the EPHB2-
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variant. In the absence of Cvx, no phosphorylation of EPHB2 was observed in WT and 
mutant EPHB2 (Figure 7A). RBL-2H3 cells activation by Cvx (1 nM), led to 
phosphorylation of WT and mutant EPHB2 but to a lesser extent for the latter (50% of 
WT-EPHB2) indicating that GPVI activation can activate EPHB2 in the absence of 
ephrin-EPHB2 interaction. 
For the patients, we found that the abnormal platelet response was not dependent on 
cell-cell contact thus excluding a role for the ephrin ligands EPHB2-GPVI cross-talk. To 
confirm these results we tested the capacity of EPHB2 to form clusters in the presence 
of an ephrin-Fc ligand in cell line considering that EPHB2 clustering by ephrin mimics 
EPHB2 response to cell-cell contact. First, WT-EPHB2 clustering increased with the 
level of recombinant WT-EPHB2 in RBL-2H3 cells (Figure 7B). No statistical difference 
was seen for the EPHB2 mutant in the presence or absence of Cvx and whatever the 
level of GFP-WT and -EPHB2-variant overexpressed (Figure 7B). Altogether, these 
results indicate that the EPHB2/p.R745C variant interferes with the first steps of cell 
activation in a contact-independent manner but has no direct functional effect in 
conditions of cell-cell contact.  
 
Discussion 
Evidence is growing that EPHB2 plays major roles in platelet function. Here we identified 
a new inherited platelet bleeding disorder affecting the EPHB2 gene in two siblings from 
a consanguineous family. Both are homozygous for the missense EPHB2/p.R745C 
variant whereas the asymptomatic parents were heterozygous for this variant. Both 
patients exhibited recurrent bleeding and normal or slightly decreased platelet counts. 
Platelet functions (aggregation, secretion induced by different agonists, thrombus 
formation on a collagen matrix) and αIIbβ3 activation were severely impaired. In 
contrast, clot retraction and adhesion on a fibrinogen matrix under flowing blood were 
only moderately affected. This indicates that the EPHB2 variant mostly affects αIIbβ3 
inside-out rather than outside-in signaling.  
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This variant identified by WES was selected among a group of homozygous variants 
common to both siblings and in an heterozygous state in both parents and (Table S3) on 
the basis of similarities between patients’ platelet phenotype and platelet defects 
reported in transgenic mice expressing EPHB2 with the cytoplasmic domain replaced by 
β-galactosidase.15 Few inherited platelet function disorders affecting several agonists 
have been described, the most common being Glanzmann’s thrombasthenia and more 
recently the CalDAG-GEFI related-disorder20 a severe bleeding disorder resulting from a 
signaling protein defect, primarily involving the inside-out activation of αIIbβ3.21,22 The 
abnormalities for EPHB2 were not limited to platelet function but also concerned platelet 
morphology with occasional thin and abnormally long platelets completely different from 
the large platelets that characterize macrothrombocytopenia (MYH9-RD, FLNA-RD, 
BSS, VWD2B) where the majority of platelets are spheroid and of large size with an 
increased small diameter.23 Nonetheless, this observation suggests a role for EPHB2 in 
platelet biogenesis. 
The defect in platelet functional responses to several agonists was particularly evident 
for collagen and Cvx. In the absence of platelet-to-platelet contact, proximal GPVI 
signaling in the patients’ EPHB2 was characterized by an impaired phosphorylation of 
Lyn, FcRγ and Syk suggesting that EPHB2 acts directly on GPVI and independently of 
its ligand, ephrin (that is dependent upon signaling processes involving direct contact 
between cells). GPVI activation triggered auto-phosphorylation of both WT and 
EPHB2/p.R745C but to a lesser extent for the latter suggesting impaired kinase activity. 
Interestingly, it has been shown that the auto-phosphorylation site of EPHB2 was the 
predominant binding site for the tyrosine kinase Src.24 Thus a direct or indirect 
association of EPHB2 with Src kinases (Fyn and Lyn) constitutively bound to GPVI is an 
attractive possibility and should be tested. In good agreement with our observation, 
platelets from transgenic mice for β-galactosidase-EPHB2 displayed diminished 
phosphorylation of Akt and PLCγ2, similar to what we observed in the patients’ platelets. 
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Surprisingly phosphorylation of Src, Lyn and Syk was normal in EPHB2-βGal mice but 
low in our patient. The reason for this difference is unclear, and may lie in the difference 
between the deletion of (or its swapping for β-galactosidase) the entire cytoplasmic tail 
of EPHB2 and the Arg:Cys missense mutation, or in species differences.  
Another important question was what happens when the ephrin binds to 
EPHB2/p.R745C, conditions encountered in platelet aggregation. Indeed, the interaction 
of EPH and ephrinB1, the only ephrin identified in platelets have been shown to 
contribute to sustained platelet aggregation.14 The clustering of EPHB2/p.R745C, 
quantified after addition of ephrin B1, was not significantly affected: consequently we 
speculate that the p.R745C variant does not affect EPHB2-ephrin B1 ligand-mediated 
platelet-platelet contact and thus thrombus stability. These data are in agreement with 
the EPHB2-β-Gal transgenic mouse model, where replacement of EPHB2 cytoplasmic 
tail by β-Gal does not diminish clustering and signaling through ephrinB1.15 The impaired 
platelet aggregation was essentially the result of the absence of αIIbβ3 activation due to 
impaired GPVI proximal signaling. 
While an inherited GPVI defect leads only to a mild bleeding phenotype,25 both of our 
patients with the EPHB2 variant exhibit a severe bleeding phenotype strongly suggesting 
that EPHB2 is involved in other regulatory platelet or vascular functions. Most likely this 
is because thrombin and ADP pathways are also strongly impaired, as shown on our 
aggregation and secretion studies with these agonists. Moreover, whereas PAR4-AP-
induced PKCs activity and Ca2+ mobilization were normal in P1, Src kinase activity was 
inhibited indicating that EPHB2 plays a relevant role at a distal level of G-coupled 
receptors. The fact that EPHB2/p.R745C affects the phosphorylation of Lyn and Src 
induced respectively by Cvx and PAR4-AP, suggests that this EPHB2/p.R745C inhibits 
phosphatases involved in the dephosphorylation of inhibitory tyrosine residues of Src 
required for its activation.19 
For personal use only.on October 14, 2018. by guest  www.bloodjournal.orgFrom 
 17
In summary, we describe a new inherited platelet disorder of a EPHB2/p.R745C variant 
characterized by a bleeding syndrome, abnormal elongated platelets and a severe 
platelet function defect. Importantly, this EPHB2 variant alters GPVI signaling at the level 
of the GPVI receptor in the absence of cell-cell contact excluding involvement of ephrin 
binding during the initial platelet activation and GPCR signaling. Despite documented 
EPHB2 expression in many cell types, the absence of associated clinical signs (other 
than the bleeding syndrome) in the patients suggests that the effects of this variant are 
essentially restricted to the megakaryocyte-platelet lineage, most likely because of the 
absence of compensatory mechanisms (other EPH receptors?) in this lineage, present in 
other tissues.  
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Figure Legends 
Figure 1: Identification of EPHB2 mutation. In A, the panel corresponds to the family 
tree (boxes, males and circles, females), the variant is indicated for P1 and P2 in solid 
black, while parents heterozygous for the mutation are indicated as half black box and 
circle ("+" signifies presence of the variant in one allele and "-" the wild type in the other 
allele). In panel B are shown Sanger sequences surrounding the mutation (arrow) within 
the EPHB2 gene for patient P1 (upper sequence, homozygote), the mother 
(heterozygote) and an unaffected control. The panel C corresponds to the schematic 
representation of identified domains of the protein EPHB2, (Fn signifies fibronectin and 
SAM sterile alpha motif). In panel D, phosphorylation of EPHB2 (EPHB2-pY594/604) in 
the presence or absence of Cvx (800 pM) was assessed in control and P1 platelets. 
Vertical lines have been inserted to indicate a repositioned gel lane. 
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Figure 2: EPHB2 mutation affects platelet morphology. 
Illustration of the typical platelet ultrastructure for control (upper panel) and patients (P1) 
a-c, (P2) d-g, by transmission electron microscopy (TEM). Panels a-b) show elongated 
platelets P1 with increased maximal diameter and a discoid shape containing few 
granules and the abnormal presence of membrane complexes (MC). Panel a) shows 
examples of platelets with a sickle shape, extensions of the plasma membrane 
suggesting a defect of fragmentation (*). Panel c) corresponds to what appears to be a 
fragment of a megakaryocyte (MK) with the aspect of an unfragmented proplatelet. 
Panels d-g correspond to platelets from P2. In d) discoid platelets with numerous 
membrane complexes. In panel f) a lower magnification shows the heterogeneity in 
platelet shape with some discoid and thin while others are round. In panel e) an 
apparent preplatelet with a barbell-shaped appearance. In panel g) is shown again an 
unfragmented MK. Scale bars indicated the magnification.  
 
Figure 3: Platelet aggregation, secretion and αIIbβ3 activation induced by ADP or 
thrombin are impaired in both patients. 
(A-C) Aggregation of washed platelets was initiated by various concentrations of ADP 
(10 and 20 μM), thrombin (25 and 50 mU/mL) during 3 minutes. Aggregation was 
expressed as the percentage change in light transmission, with the value of the blank 
(buffer without platelets) set at 100%. Tracings are representative of at least two 
experiments per patient. (B-D) Quantification of activated αIIbβ3 at the surface of 
washed platelets was assessed by flow cytometry by binding of the specific mAb PAC1 
to control and P1 and P2 platelets upon activation with ADP (5 and 10 μM), thrombin (50 
and 100 mU/mL). (E-F) Quantification of P-selectin exposure was assessed by flow 
cytometry using anti-P selectin antibody and dense granule release with an ATP 
determination kit, respectively, to control and P1 platelets upon activation by thrombin 
(50 and 100 mU/mL). These results are representative of 2 experiments for each patient. 
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Figure 4: Down-regulation of platelet signaling induced by PAR4-AP.  
(A) Aggregation of washed platelets for P1 and P2 was initiated by PAR4-AP (50 μM) 
during 3 minutes. Aggregation was expressed as the percentage change in light 
transmission, with the value of the blank (buffer without platelets) set at 100%. Tracings 
are representative of at least two experiments per patient. (B) Quantification of activated 
αIIbβ3 at the surface of washed platelets was assessed by flow cytometry by binding of 
the specific mAb PAC1 to control, P1 and P2 platelets upon activation by PAR4-AP (100 
to 200 μM) (C) Quantification of P-selectin expression at the surface of washed platelets 
was assessed by flow cytometry by binding of the specific anti-P selectin antibody to 
control, P1 and P2 platelets upon activation by PAR4-AP (100 to 200 μM). These results 
are representative of 2 experiments for each patient. (D) Ca2+ mobilization was assessed 
in unstirred platelets pre-incubated with the cytosolic Ca2+ fluorescent probe Oregon 
green BAPTA-AM after stimulation by PAR4-AP (100 and 200 μM) by flow cytometry in 
conditions of no external Ca2+ (1mM EGTA). (E-F) Phosphorylation of PKC substrates 
and of Src-Y418 of control and P1 platelets activated by PAR4-AP (0 to 300 µM) was 
assessed by immunoblotting using an anti-PKC-substrates-p-S and an anti-Src-p-Y418, 
respectively. These results are representative of 2 experiments. Quantification of Src 
phosphorylation (Src-p-Y418) was the average of the 2 experiments. 
 
Figure 5: Platelet aggregation and αIIbβ3 activation induced by Cvx are altered in 
both patients. 
(A) Aggregation of washed platelets was initiated by increasing concentrations of Cvx 
(200 to 800 pM) during 3 minutes. Aggregation was expressed as the percentage 
change in light transmission, with the value of the blank (buffer without platelets) set at 
100%. Tracings are representative of at least two experiments per patient. (B) 
Quantification of activated αIIbβ3 at the surface of washed platelets was assessed by 
flow cytometry by binding of the mAb PAC1 to control and P1 and P2 platelets upon 
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activation with Cvx (200 to 800 pM). (C) The same experiment was conducted in the 
presence of apyrase (2U/mL) and indomethacin (10 μM). These results are 
representative of 2 experiments for each patient. (D) Adherence and thrombus size were 
investigated on collagen matrix (50 μg/mL) in the presence or absence of apyrase 
(2U/mL) and indomethacin (10 μM) at high shear rate (1500 s-1) after 3 minutes. Platelet 
adhesion was expressed as covered surface (%) and thrombus size as total integrated 
fluorescence intensity (IFI) from 2 experiments carried out in triplicate. Data are 
presented as the mean ± SEM and statistical differences were determined using 1-way 
ANOVA followed by Tukey’s multiple comparison test; * P<0.05, ** P<0.01, *** P<0.001.  
 
Figure 6: Downregulation of platelet signaling induced by Cvx.  
Washed P1 platelets in suspension were activated by Cvx (200 or 800 pM) for 3 minutes 
in the absence of stirring and in the presence of apyrase (2U/mL) and indomethacin (10 
μM). (A) Ca2+ mobilization was assessed in unstirred platelets pre-incubated with the 
cytosolic Ca2+ fluorescent probe Oregon green BAPTA-AM after stimulation by Cvx (200 
to 800 pM) by flow cytometry in conditions of no external Ca2+ (1mM EGTA). (B and C) 
Tyrosine phosphorylation of Akt (p-S473), Syk (p-Y525/526), PLCγ2 (p-Y1217) and FcRγ 
was assessed by immunoblotting using an anti-Akt-P, an anti-Syk-P, an anti-PLCγ2-P 
and an anti-phosphotyrosine antibodies respectively. These results are representative of 
2 experiments. (D) Lyn phosphorylation on Y396 was assessed by immunoblotting using 
an anti-Lyn-P. Data presented are means ± SEM of 4 independent experiments (* 
P<0.05, ** P<0.01, unpaired Student t test).  
 
Figure 7: Effect of EPHB2/p.R745C mutation on auto-phosphorylation of EPHB2 
and ephrin-induced clustering. 
RBL-2H3 cells transfected with WT and mutant EPHB2 constructs were plated on 
fibrinogen -coverslips for 1 hour. (A) Over-expression and phosphorylation of EPHB2-
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WT and EPHB2/p.R745C (EPHB2-Mu) variant after activation with Cvx (1nM) was 
quantified by western blotting using an anti-EPHB2 and EPHB2-pY594/Y604 antibodies. 
Results are representative of 3 independent experiments. (B) Clustering of EPHB2 was 
performed by adding ephrinB1-Fc dimeric ligand to transfected cells stimulated by Cvx 
(1 nM) and plated on fibrinogen-coated coverslips for 30 min. After various washes, 
binding of ephrinB1-Fc and level of EPHB2-GFP for the corresponding cell were 
quantified by fluorescence microscopy (Nikon Eclipse E600). Total integrated 
fluorescence intensity (IFI) from 3 independent experiments is presented as the mean ± 
SEM.  
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